A Study in Patients With Atopic Eczema to Test How Effective BI 655130 is and How Well it is Tolerated

PHASE2CompletedINTERVENTIONAL
Enrollment

51

Participants

Timeline

Start Date

February 12, 2019

Primary Completion Date

January 17, 2020

Study Completion Date

July 22, 2020

Conditions
Dermatitis, Atopic
Interventions
DRUG

BI 655130

Solution for infusion

DRUG

Placebo

Solution for infusion

Trial Locations (23)

33126

Finlay Medical Research Corp, Miami

33612

University of South Florida, Tampa

33613

ForCare Clinical Research, Inc., Tampa

33912

Clinical Physiology Associates, Fort Myers

46168

The Indiana Clinical Trials Center, PC, Plainfield

73118

Unity Clinical Research, Oklahoma City

75230

Dermatology Treatment and Research Center, PA, Dallas

77598

Center for Clinical Studies, Webster

78213

Progressive Clinical Research, San Antonio

85260

Center for Dermatology and Plastic Surgery, Scottsdale

T6G 2B7

University of Alberta Hospital (University of Alberta), Edmonton

A1C 2H5

NewLab Clinical Research Inc., St. John's

H2X 2V1

Innovaderm Research Inc., Montreal

480-1195

Aichi Medical University Hospital, Aichi, Nagakute

810-8563

National Hospital Organization Kyushu Medical Center, Fukuoka, Fukuoka

830-0011

Kurume University Hospital, Fukuoka, Kurume

064-0807

Hosui General Medical Clinic, Hokkaido, Sapporo

240-0004

Tennocho Ekimae Dermatology and Allergology, Kanagawa, Yokohama

602-8566

University Hospital Kyoto Prefectural University of Medicine, Kyoto, Kyoto

852-8501

Nagasaki University Hospital, Nagasaki, Nagasaki

545- 8586

Osaka City University Hospital, Osaka, Osaka

193-0998

Tokyo Medical University Hachioji Medical Center, Tokyo, Hachioji

142-8666

Showa University Hospital, Tokyo, Shinagawa-ku

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY